Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Shares of organ transplant innovator TransMedics Group ( TMDX -1.41%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...

TransMedics’ stock price has dropped $9.84, or 13%, since Scorpion released a report, titled “Walk Like An Egyptian,” leveling serious allegations against the company, including fraud ...

Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

TransMedics is the subject of a report issued by Scorpion Capital on January 10, 2025. The report claims that in "20 years of shorting, TransMedics is the most extreme and grotesque healthcare fraud ...

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.

Last Friday, Scorpion Capital published a 342-page short report -- yes, 342 pages! -- detailing an alleged six-month investigation into TransMedics and its business practices. TransMedics has ...

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.